{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/bronchiectasis/prescribing-information/ciprofloxacin/","result":{"pageContext":{"chapter":{"id":"04c99c8f-7a1d-55f0-85a2-6d0e1bc3e4e3","slug":"ciprofloxacin","fullItemName":"Ciprofloxacin","depth":2,"htmlHeader":"<!-- begin field 3202f4fd-9c70-447a-b853-ac0d010a86fc --><h2>Ciprofloxacin</h2><!-- end field 3202f4fd-9c70-447a-b853-ac0d010a86fc -->","summary":null,"htmlStringContent":"<!-- begin item 77c195e6-a847-4e53-afd1-db3b8fa55f6f --><!-- end item 77c195e6-a847-4e53-afd1-db3b8fa55f6f -->","topic":{"id":"96a8622b-46f5-55fa-b729-6748e3d98c98","topicId":"26fab339-e333-44ec-a481-de87a29052f3","topicName":"Bronchiectasis","slug":"bronchiectasis","lastRevised":"Last revised in January 2021","chapters":[{"id":"43d88c30-f768-5e1c-a6ea-5596c5577fb5","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"ac4fde9a-5fd3-5ed9-9201-f714bda470bb","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"0b34af83-d49a-5145-8589-e8748b8646c0","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"04eeb1ae-4fc3-5418-83a2-b62587d8bdda","slug":"changes","fullItemName":"Changes"},{"id":"dbd8ad5a-871c-59b8-9729-444e11ac9df1","slug":"update","fullItemName":"Update"}]},{"id":"b89644c6-805f-50b4-991d-36bb2b0fbf67","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"d38de329-73b8-5fed-83ef-f836b765cd3f","slug":"goals","fullItemName":"Goals"},{"id":"3c116665-5586-5551-909c-0efc1ef0be62","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"60e13bc0-e351-5c39-b8ff-9a8d4514bf16","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"2ee37cc0-9ff4-5bbd-ab3f-0a30cb904bb5","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"d155aa4f-7dfe-575d-a7dd-a87774f4cbad","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"07c3e24b-c950-516e-9070-5441a07b3791","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"5146c866-f0a7-54a6-a5ac-8aff4b385cc6","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"e2107a7e-b7c3-5ba9-94e4-6217ea79a3f2","slug":"definition","fullItemName":"Definition"},{"id":"39df7c47-de08-57ae-aa40-89a7d4d7b031","slug":"causes","fullItemName":"Causes"},{"id":"ac4d346e-97d4-5d84-a704-fbdcf56be7f4","slug":"prevalence","fullItemName":"Prevalence"},{"id":"e07a8b0b-866c-5789-85ef-020a5b19b620","slug":"prognosis-complications","fullItemName":"Prognosis and complications"}]},{"id":"ef5c5e7b-3cf4-5939-85e0-b61cae41f945","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"ce267b5b-70dd-52bd-ad83-6123bd42fa0d","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"c605c0b9-0519-50e1-abd8-2dc47de7278a","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"},{"id":"23a1627d-30f7-5ba4-95f8-060faf797f51","slug":"suspected-infective-exacerbation-diagnosis","fullItemName":"Suspected infective exacerbation diagnosis"}]},{"id":"5a5846fa-c8b4-5cd4-b2d3-770c3dc00ba2","fullItemName":"Management","slug":"management","subChapters":[{"id":"0180d43c-dd8d-5a87-915c-629542f782fe","slug":"suspected-bronchiectasis","fullItemName":"Scenario: Suspected bronchiectasis"},{"id":"290c51ae-6521-5c03-b12e-117e40c88883","slug":"infective-exacerbation","fullItemName":"Scenario: Infective exacerbation"},{"id":"1e90ec28-8eea-5ab7-ac76-2df1ace279de","slug":"covid-19","fullItemName":"Scenario: COVID-19"}]},{"id":"ba1a593e-f80b-5c5f-be50-5979b491bc70","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"6db0266e-4d15-5eec-b2c0-ed20f472eeb5","slug":"azithromycin","fullItemName":"Azithromycin"},{"id":"a98b5813-5589-5247-9c65-e9ae534d88c2","slug":"amoxicillin","fullItemName":"Amoxicillin"},{"id":"04c99c8f-7a1d-55f0-85a2-6d0e1bc3e4e3","slug":"ciprofloxacin","fullItemName":"Ciprofloxacin"},{"id":"26b521e3-9c5e-5a7c-956b-7f3f39f2e58c","slug":"clarithromycin","fullItemName":"Clarithromycin"},{"id":"6cd6079a-be84-5279-9d10-e3bf4653c049","slug":"co-amoxiclav","fullItemName":"Co-amoxiclav"},{"id":"8ed4a900-3e69-51c0-8cd5-c2b0bee9bfe2","slug":"doxycycline","fullItemName":"Doxycycline"},{"id":"5217d027-064d-5543-93b0-7e8bb1a1c0fc","slug":"erythromycin","fullItemName":"Erythromycin"},{"id":"cf1fbf18-e60a-54f7-bbc4-2a30ab37f565","slug":"flucloxacillin","fullItemName":"Flucloxacillin"},{"id":"8e888abe-cb05-5343-b6e3-547dea7312cc","slug":"beta-2-agonists","fullItemName":"Beta-2 agonists"}]},{"id":"118b4e08-e6ae-510a-b2f5-51b109ef3395","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"ecf8de37-d8f0-5ced-af38-9be20fa73de9","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"1c227675-02ea-5c9e-a927-e385987adf53","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"f74bbe64-1998-528f-b811-df2a14219de7","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"2a925d45-6865-5cd5-9624-23da53ee221a","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"a6ff3076-9be6-55b4-b373-f40cb3045f2c","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"67608f46-5eba-58f9-86e3-0e0e3f57d921","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"3fae7f8d-20fb-5fe6-af57-64882afceb3a","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"ba1a593e-f80b-5c5f-be50-5979b491bc70","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"71bb67e8-d118-5625-b078-e996c178e092","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field d7e8c933-575e-4d04-bfc7-ac0d010a86fc --><h3>What contraindications and cautions are associated with ciprofloxacin?</h3><!-- end field d7e8c933-575e-4d04-bfc7-ac0d010a86fc -->","summary":null,"htmlStringContent":"<!-- begin item 5fe8540b-24c5-4e41-93eb-7a657e00ccf7 --><!-- begin field 200cb07b-ee3c-43f5-87a3-ac0d010a86fc --><ul><li><strong>Do not prescribe ciprofloxacin to:</strong><ul><li>Pregnant women — quinolones have been shown to cause arthropathy in animal studies.</li><li>Breastfeeding women.</li><li>People with a history of tendon disorders related to quinolone use.</li><li>People taking tizanidine concomitantly.</li></ul></li><li><strong>Prescribe ciprofloxacin with caution in people with:</strong><ul><li>Epilepsy, or conditions that predispose to seizures, and in people taking other medication that may predispose to seizures, as quinolones can lower the seizure threshold.<ul><li>Quinolones may induce convulsions in patients with or without a history of convulsions, and taking nonsteroidal anti-inflammatory drugs at the same time may also induce them.</li></ul></li><li>Diabetes — may affect blood glucose. Blood glucose should be monitored closely.</li><li>Glucose-6-phosphate dehydrogenase deficiency — haemolytic reactions have been reported.</li><li>A history of tendonitis — quinolones can very rarely cause tendon damage, and the risk of tendon rupture is increased by co-administration of corticosteroid.<ul><li>A single dose for treatment of gonorrhoea is unlikely to be significant.</li></ul></li><li>Impaired renal function — dose adjustments may be required. </li><li>Impaired liver function — liver damage can occur. </li><li>Conditions that predispose to QT interval prolongation:<ul><li>Congenital long QT syndrome.</li><li>Concomitant use of drugs that are known to prolong the QT interval (for example Class IA and III anti-arrhythmics, tricyclic antidepressants, macrolides, antipsychotics).</li><li>Uncorrected electrolyte imbalance (for example hypokalaemia or hypomagnesaemia).</li><li>Cardiac disease (for example, heart failure, myocardial infarction, or bradycardia).</li><li>Electrolyte disturbances.</li></ul></li><li>History of a psychotic disorder — there have been reports of suicidal thoughts or self-endangering behaviour after use quinolones. </li><li>Myasthenia gravis — symptoms can be exacerbated.</li><li>Positive family history of aneurysm disease or congenital heart valve disease.</li><li>Pre-existing aortic aneurysm and/or dissection or heart valve disease, or in presence of other risk factors or conditions predisposing for:<ul><li>Both aortic aneurysm and dissection and heart valve regurgitation/incompetence (e.g. connective tissue disorders such as Marfan syndrome or Ehlers-Danlos syndrome, Turner syndrome, Behcet's disease, hypertension, rheumatoid arthritis) <em>or additionally</em></li><li>Aortic aneurysm and dissection (such as vascular disorders including Takayasu arteritis or giant cell arteritis, or known atherosclerosis, or Sjögren's syndrome) <em>or additionally</em></li><li>Heart valve regurgitation/incompetence (such as infective endocarditis).</li></ul></li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/bronchiectasis/references/\">ABPI, 2020c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/bronchiectasis/references/\">ABPI, 2020d</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/bronchiectasis/references/\">Joint Formulary Committee, 2020</a>]</p><!-- end field 200cb07b-ee3c-43f5-87a3-ac0d010a86fc --><!-- end item 5fe8540b-24c5-4e41-93eb-7a657e00ccf7 -->","subChapters":[]},{"id":"3c0e4bd0-8c1b-5ac7-ae4b-84a752e99d63","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 62ef1d49-b8bc-4be5-b60f-ac0d010a86fc --><h3>What are the adverse effects of ciprofloxacin?</h3><!-- end field 62ef1d49-b8bc-4be5-b60f-ac0d010a86fc -->","summary":null,"htmlStringContent":"<!-- begin item f3ae7906-5073-4c7c-b82a-509713a335dd --><!-- begin field 7be87ca9-59b0-4466-923c-ac0d010a86fc --><ul><li><strong>Gastrointestinal</strong> — diarrhoea, nausea (common), vomiting, dyspepsia, flatulence, gastrointestinal and abdominal pains (uncommon).<ul><li>Rarely: pseudomembranous colitis (for more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/diarrhoea-antibiotic-associated/\">Diarrhoea - antibiotic associated</a>).</li></ul></li><li><strong>Musculoskeletal</strong> — pain, arthralgia (uncommon).<ul><li>Rarely: myalgia, arthritis.</li><li>Very rarely: muscle weakness, tendonitis, tendon damage — this may occur within 48 hours of starting treatment, or months after stopping. Risk of tendon rupture is increased by co-administration of corticosteroids and in people aged over 60 years.</li></ul></li><li><strong>Nervous system</strong> — headache, dizziness, sleep disorders, taste disorders (uncommon).<ul><li>Rarely: tremor, vertigo, lowering of the seizure threshold — this may trigger seizures. </li></ul></li><li><strong>Psychiatric</strong> — hyperactivity, agitation (uncommon).<ul><li>Rarely: confusion, anxiety, depression, hallucinations.</li></ul></li><li><strong>Skin</strong> — rash, pruritus, urticaria.<ul><li>Rarely: Stevens–Johnson syndrome, erythema multiforme, toxic epidermal necrolysis anaphylaxis, drug rash with eosinophilia, systemic symptoms (DRESS), acute generalized exanthematous pustulosis (AGEP).</li></ul></li><li><strong>Other adverse effects include:</strong><ul><li>Anaphylaxis.</li><li>Hepatic impairment, hepatitis.</li><li>Renal impairment.</li><li>Tachycardia.</li><li>Tinnitus.</li><li>Visual disturbances.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/bronchiectasis/references/\">ABPI, 2020c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/bronchiectasis/references/\">Joint Formulary Committee, 2020</a>]</p><!-- end field 7be87ca9-59b0-4466-923c-ac0d010a86fc --><!-- end item f3ae7906-5073-4c7c-b82a-509713a335dd -->","subChapters":[]},{"id":"956e237d-6b3b-570f-9b06-692045248b5c","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 097bd77a-1fb3-40e7-b05a-ac0d010a86fc --><h3>What drug interactions are important for ciprofloxacin?</h3><!-- end field 097bd77a-1fb3-40e7-b05a-ac0d010a86fc -->","summary":null,"htmlStringContent":"<!-- begin item 5f555f40-e5b4-4f49-9101-d2bcf9c53392 --><!-- begin field 5eeef88c-75c3-495d-9f83-ac0d010a86fc --><ul><li><strong>Antacids (containing aluminium, calcium, or magnesium) and other medications containing iron or zinc</strong> — these reduce the absorption of ciprofloxacin if taken concurrently.<ul><li>Ciprofloxacin should be taken at least 2 hours before these preparations.</li></ul></li><li><strong>Ciclosporin</strong> — increased concentrations and nephrotoxicity might occur in a small number of patients.</li><li><strong>Ergot alkaloids</strong> (such as ergotamine and dihydroergotamine) — concurrent use with ciprofloxacin may result in acute ergot toxicity. Concurrent use is contraindicated.</li><li><strong>Methotrexate</strong> — plasma levels of methotrexate may be increased. The manufacturer recommends that concomitant use is avoided.<ul><li>If concurrent use is necessary, monitor methotrexate levels.</li></ul></li><li><strong>Nonsteroidal anti-inflammatory drugs (NSAIDs) </strong>— possible increased risk of seizures when quinolones are given with NSAIDs. Avoid concurrent use in people with epilepsy or people predisposed to seizures, or monitor them very closely.</li><li><strong>Oral hormonal contraception</strong> — additional contraceptive precautions are not required during or after courses of ciprofloxacin.<ul><li>However, women should be advised about the importance of correct contraceptive practice if they experience vomiting or diarrhoea. For further information, see the sections on vomiting or diarrhoea in the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-combined-hormonal-methods/\">Contraception - combined hormonal methods</a> and <a class=\"topic-reference external-reference\" href=\"/topics/contraception-progestogen-only-methods/\">Contraception - progestogen-only methods</a>.</li></ul></li><li><strong>Phenytoin</strong> — concurrent administration of ciprofloxacin can cause an increase or decrease in serum phenytoin levels. Monitor phenytoin levels.</li><li><strong>Strontium ranelate </strong>— the absorption of quinolones is reduced by strontium ranelate so they should not be given together.</li><li><strong>Theophylline, aminophylline </strong>— ciprofloxacin increases the plasma concentration of theophylline and may do the same to aminophylline, leading to possible increased risk of convulsions. Monitor closely.</li><li><strong>Tizanidine </strong>— ciprofloxacin markedly increases the plasma concentration of tizanidine (increased risk of toxicity). Avoid concomitant use.</li><li><strong>Typhoid vaccine</strong> — antibacterials might reduce the immune response. The World Health Organization (WHO) recommends that the antibacterial is stopped from 3 days before to 3 days after receiving live oral typhoid vaccine.</li><li><strong>Warfarin </strong>— rarely, ciprofloxacin may enhance the anticoagulant effect, increasing the risk of bleeding. Monitor the international normalized ratio (INR) within 3–5 days of starting ciprofloxacin, frequently during, and shortly after administration.</li><li><strong>Zolmitriptan</strong> — quinolones increase the plasma concentration of zolmitriptan by inhibiting its metabolism. Manufacturer recommends a maximum dose of 5 mg in 24 hours in people taking a quinolone.</li><li><strong>Drugs that prolong the QT interval </strong>(such as Class IA and III anti-arrhythmics, tricyclic antidepressants, macrolides, and antipsychotics) — very rare cases of QT interval prolongation have been reported in people taking quinolones and they should therefore be prescribed with caution alongside drugs known to prolong the QT interval.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/bronchiectasis/references/\">Preston, 2020</a>]</p><!-- end field 5eeef88c-75c3-495d-9f83-ac0d010a86fc --><!-- end item 5f555f40-e5b4-4f49-9101-d2bcf9c53392 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}